RATIONALE-306 Trial

Content Type: Reading

RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025

RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 study of tislelizumab combined with platinum and fluoropyrimidine chemotherapy compared to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Reading
8 Aug 2025

RATIONALE-302 (NCT03430843) is a global Phase 3 study of tislelizumab vs investigator-chosen chemotherapy as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025

MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed/refractory CLL.

Reading
8 Aug 2025

CaDAnCe-101 (NCT05006716) is a Phase 1/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).

Reading
8 Aug 2025